Argent BioPharma Limited
RGT.L · LSE
6/30/2024 | 12/31/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | £19,142 | £8,837 | £1,277 | £940 |
| - Cash | £703 | £3,466 | £240 | £638 |
| + Debt | £1,045 | £5,158 | £575 | £5,648 |
| Enterprise Value | £19,484 | £10,529 | £1,613 | £5,950 |
| Revenue | £154 | £321 | £380 | £1,499 |
| % Growth | -52% | -15.7% | -74.6% | – |
| Gross Profit | -£199 | £39 | £62 | £695 |
| % Margin | -129.1% | 12.1% | 16.2% | 46.3% |
| EBITDA | -£4,989 | -£4,015 | -£3,622 | -£4,371 |
| % Margin | -3,243.3% | -1,252.6% | -952.6% | -291.5% |
| Net Income | -£5,516 | -£3,783 | -£5,214 | -£6,128 |
| % Margin | -3,585.8% | -1,180.3% | -1,371.4% | -408.7% |
| EPS Diluted | -0.11 | -0.16 | -1.58 | -2.37 |
| % Growth | 31.3% | 89.9% | 33.3% | – |
| Operating Cash Flow | -£3,565 | -£4,227 | -£2,744 | -£3,803 |
| Capital Expenditures | -£65 | -£9 | £24 | -£133 |
| Free Cash Flow | -£3,630 | -£4,236 | -£2,720 | -£3,936 |